Endeavor

New Cell Therapy Takes Advantage of a ‘Natural Killer’

Researchers study the use of natural killer cells instead of T cells in cellular immunotherapy

Accidental Discovery Could Lead to Future Cancer Therapy

Researchers in Europe discover T cell that may help detect and kill several cancers

Bridging Therapy Not Recommended for All CAR T Patients

New data presented by Moffitt shows poorer outcome for patients who receive bridging therapy prior to CAR T-cell therapy.

Breakthroughs Running on Miles for Moffitt Grant

Funding builds momentum to continue critical cancer research.

The Power of CAR T in Solid Tumor Treatment

CAR T therapy involves a patient’s own T cells that have been genetically engineered to target a patient’s own specific cancer.

CAR T Therapy Safe for Older Patients

Moffitt’s closer look at clinical trial data could expand therapy’s use and effectiveness.

Nearly 40 Percent of CAR T Patients Remain in Remission

Many ZUMA-1 participants remain in remission and more than half of those treated remain alive.

New Study Shows CAR T-cell Therapy for Lymphoma Lives up to its Press

Seventeen cancer centers compare real world outcomes of diffuse large B cell lymphoma patients treated with Yescarta® to ZUMA-1 clinical trial data

Moffitt Honors CAR T Patient during Veterans Day Ceremony

Moffitt honored Floyd Cook, other veterans during the annual flag-raising ceremony.